These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 11702180)

  • 1. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging.
    Wang YX; Hussain SM; Krestin GP
    Eur Radiol; 2001; 11(11):2319-31. PubMed ID: 11702180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Superparamagnetic iron oxide particles: current state and future development].
    Taupitz M; Schmitz S; Hamm B
    Rofo; 2003 Jun; 175(6):752-65. PubMed ID: 12811686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application.
    Wang YX
    Quant Imaging Med Surg; 2011 Dec; 1(1):35-40. PubMed ID: 23256052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of superparamagnetic iron oxide contrast agents for liver magnetic resonance imaging.
    Wang YX
    World J Gastroenterol; 2015 Dec; 21(47):13400-2. PubMed ID: 26715826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spatial Organization of Superparamagnetic Iron Oxide Nanoparticles in/on Nano/Microsized Carriers Modulates the Magnetic Resonance Signal.
    Lee MK; Clay NE; Ko E; Smith CE; Chen L; Cho N; Sung HJ; DiPietro L; Lee J; Kong H
    Langmuir; 2018 Dec; 34(50):15276-15282. PubMed ID: 30458616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient.
    Vogl TJ; Hammerstingl R; Schwarz W; Kümmel S; Müller PK; Balzer T; Lauten MJ; Balzer JO; Mack MG; Schimpfky C; Schrem H; Bechstein WO; Neuhaus P; Felix R
    Invest Radiol; 1996 Nov; 31(11):696-708. PubMed ID: 8915751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Labeling of mesenchymal stem cells with different superparamagnetic particles of iron oxide and detectability with MRI at 3T].
    Ittrich H; Lange C; Dahnke H; Zander AR; Adam G; Nolte-Ernsting C
    Rofo; 2005 Aug; 177(8):1151-63. PubMed ID: 16021549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted dual-contrast T1- and T2-weighted magnetic resonance imaging of tumors using multifunctional gadolinium-labeled superparamagnetic iron oxide nanoparticles.
    Yang H; Zhuang Y; Sun Y; Dai A; Shi X; Wu D; Li F; Hu H; Yang S
    Biomaterials; 2011 Jul; 32(20):4584-93. PubMed ID: 21458063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spin-lock MR enhances the detection sensitivity of superparamagnetic iron oxide particles.
    Moonen RP; van der Tol P; Hectors SJ; Starmans LW; Nicolay K; Strijkers GJ
    Magn Reson Med; 2015 Dec; 74(6):1740-9. PubMed ID: 25470118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure activity relationship of magnetic particles as MR contrast agents.
    Thomassen T; Wiggen UN; Gundersen HG; Fahlvik AK; Aune O; Klaveness J
    Magn Reson Imaging; 1991; 9(2):255-8. PubMed ID: 2034059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Citrate coated iron oxide nanoparticles with enhanced relaxivity for in vivo magnetic resonance imaging of liver fibrosis.
    Saraswathy A; Nazeer SS; Jeevan M; Nimi N; Arumugam S; Harikrishnan VS; Varma PR; Jayasree RS
    Colloids Surf B Biointerfaces; 2014 May; 117():216-24. PubMed ID: 24646453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the use of superparamagnetic hydroxyapatite nanoparticles as an agent for magnetic and nuclear in vivo imaging.
    Adamiano A; Iafisco M; Sandri M; Basini M; Arosio P; Canu T; Sitia G; Esposito A; Iannotti V; Ausanio G; Fragogeorgi E; Rouchota M; Loudos G; Lascialfari A; Tampieri A
    Acta Biomater; 2018 Jun; 73():458-469. PubMed ID: 29689381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. A review.
    Bonnemain B
    J Drug Target; 1998; 6(3):167-74. PubMed ID: 9888302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in predominant enhancement mechanisms of superparamagnetic iron oxide and ultrasmall superparamagnetic iron oxide for contrast-enhanced portal magnetic resonance angiography. Preliminary results of an animal study original investigation.
    Knollmann FD; Böck JC; Rautenberg K; Beier J; Ebert W; Felix R
    Invest Radiol; 1998 Sep; 33(9):637-43. PubMed ID: 9766048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RES-specific imaging of the liver and spleen with iron oxide particles designed for blood pool MR-angiography.
    Bremer C; Allkemper T; Baermig J; Reimer P
    J Magn Reson Imaging; 1999 Sep; 10(3):461-7. PubMed ID: 10508309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silica- and alkoxysilane-coated ultrasmall superparamagnetic iron oxide particles: a promising tool to label cells for magnetic resonance imaging.
    Zhang C; Wängler B; Morgenstern B; Zentgraf H; Eisenhut M; Untenecker H; Krüger R; Huss R; Seliger C; Semmler W; Kiessling F
    Langmuir; 2007 Jan; 23(3):1427-34. PubMed ID: 17241069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil.
    Jung CW; Jacobs P
    Magn Reson Imaging; 1995; 13(5):661-74. PubMed ID: 8569441
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.